Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 67(13): 11024-11052, 2024 Jul 11.
Article in English | MEDLINE | ID: mdl-38924388

ABSTRACT

Oncogenic mutations in the RAS gene account for 30% of all human tumors; more than 60% of which present as KRAS mutations at the hotspot codon 12. After decades of intense pursuit, a covalent inhibition strategy has enabled selective targeting of this previously "undruggable" target. Herein, we disclose our journey toward the discovery of MK-1084, an orally bioavailable and low-dose KRASG12C covalent inhibitor currently in phase I clinical trials (NCT05067283). We leveraged structure-based drug design to identify a macrocyclic core structure, and hypothesis-driven optimization of biopharmaceutical properties to further improve metabolic stability and tolerability.


Subject(s)
Drug Discovery , Proto-Oncogene Proteins p21(ras) , Animals , Dogs , Humans , Mice , Rats , Administration, Oral , Antineoplastic Agents/pharmacology , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/chemistry , Biological Availability , Dose-Response Relationship, Drug , Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors , Proto-Oncogene Proteins p21(ras)/genetics , Proto-Oncogene Proteins p21(ras)/metabolism , Structure-Activity Relationship
2.
J Med Chem ; 58(4): 1929-39, 2015 Feb 26.
Article in English | MEDLINE | ID: mdl-25625541

ABSTRACT

Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand binding efficiency. Attenuation of hERG ion channel activity inherent within the initial chemotype was guided through modulation of physicochemical properties including log D, PSA, and pKa. PSA proved most effective for prospective compound design. Further profiling of an advanced compound revealed bacterial mutagenicity in the Ames test using TA97a Salmonella strain, and subsequent study demonstrated that this mutagenicity was pervasive throughout the series. Identification of intercalation as a likely mechanism for the mutagenicity-enabled modification of the core scaffold. Implementation of a DNA binding assay as a prescreen and models in DNA allowed resolution of the mutagenicity risk, affording molecules with favorable potency, selectivity, pharmacokinetic, and off-target profiles.


Subject(s)
Amides/pharmacology , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , Spleen/enzymology , Amides/chemical synthesis , Amides/chemistry , Crystallography, X-Ray , Dose-Response Relationship, Drug , Ether-A-Go-Go Potassium Channels/genetics , Ether-A-Go-Go Potassium Channels/metabolism , Humans , Models, Molecular , Molecular Structure , Mutagenicity Tests , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Protein-Tyrosine Kinases/metabolism , Spleen/drug effects , Structure-Activity Relationship
3.
PLoS One ; 7(5): e37207, 2012.
Article in English | MEDLINE | ID: mdl-22623993

ABSTRACT

A high percentage of patients with the myeloproliferative disorder polycythemia vera (PV) harbor a Val617→Phe activating mutation in the Janus kinase 2 (JAK2) gene, and both cell culture and mouse models have established a functional role for this mutation in the development of this disease. We describe the properties of MRLB-11055, a highly potent inhibitor of both the WT and V617F forms of JAK2, that has therapeutic efficacy in erythropoietin (EPO)-driven and JAK2V617F-driven mouse models of PV. In cultured cells, MRLB-11055 blocked proliferation and induced apoptosis in a manner consistent with JAK2 pathway inhibition. MRLB-11055 effectively prevented EPO-induced STAT5 activation in the peripheral blood of acutely dosed mice, and could prevent EPO-induced splenomegaly and erythrocytosis in chronically dosed mice. In a bone marrow reconstituted JAK2V617F-luciferase murine PV model, MRLB-11055 rapidly reduced the burden of JAK2V617F-expressing cells from both the spleen and the bone marrow. Using real-time in vivo imaging, we examined the kinetics of disease regression and resurgence, enabling the development of an intermittent dosing schedule that achieved significant reductions in both erythroid and myeloid populations with minimal impact on lymphoid cells. Our studies provide a rationale for the use of non-continuous treatment to provide optimal therapy for PV patients.


Subject(s)
Enzyme Inhibitors/pharmacology , Janus Kinase 2/antagonists & inhibitors , Polycythemia Vera/drug therapy , Animals , Blotting, Western , Cell Proliferation/drug effects , Colony-Forming Units Assay , Dose-Response Relationship, Drug , Enzyme Inhibitors/therapeutic use , Erythropoietin/metabolism , Flow Cytometry , Humans , Mice , Mice, Inbred C57BL , STAT5 Transcription Factor/metabolism
4.
J Med Chem ; 54(20): 7334-49, 2011 Oct 27.
Article in English | MEDLINE | ID: mdl-21942426

ABSTRACT

The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells. In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs). This mutation led to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks. The genetic, biological, and physiological evidence suggests that JAK2 inhibitors could be effective in treating MPDs. De novo design efforts of new scaffolds identified 1-amino-5H-pyrido[4,3-b]indol-4-carboxamides as a new viable lead series. Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide (65). Compound 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.


Subject(s)
Carbolines/chemical synthesis , Indoles/chemical synthesis , Janus Kinase 2/antagonists & inhibitors , Myeloproliferative Disorders/drug therapy , Pyridines/chemical synthesis , Pyrimidines/chemical synthesis , Administration, Oral , Animals , Carbolines/pharmacokinetics , Carbolines/pharmacology , Crystallography, X-Ray , Dogs , Haplorhini , Hepatocytes/metabolism , Indoles/pharmacokinetics , Indoles/pharmacology , Janus Kinase 2/metabolism , Mice , Mice, Inbred C57BL , Models, Molecular , Molecular Structure , Phosphorylation , Polycythemia Vera/drug therapy , Pyridines/pharmacokinetics , Pyridines/pharmacology , Pyrimidines/pharmacokinetics , Pyrimidines/pharmacology , Rats , Stereoisomerism , Structure-Activity Relationship
5.
Org Lett ; 7(3): 495-8, 2005 Feb 03.
Article in English | MEDLINE | ID: mdl-15673273

ABSTRACT

[reaction: see text] The nitrogen-based nucleophile generated from azodicarboxylate and triphenylphosphine displayed an excellent reactivity toward carbonyl compounds to generate a variety of different final products depending on the substituent pattern on the carbonyl carbon. From the structures of these adducts, a straightforward mechanistic interpretation for the formation of different products is provided.


Subject(s)
Ketones/chemistry , Alcohols/chemistry , Indicators and Reagents , Models, Molecular , Molecular Conformation
6.
J Org Chem ; 69(10): 3569-71, 2004 May 14.
Article in English | MEDLINE | ID: mdl-15132574

ABSTRACT

Rhodium acetate-catalyzed hydroacylation between aldehydes and an activated form of N=N bond was achieved under mild conditions to provide efficient access to a variety of hydrazino imides. Good selectivity for the aldehydic C-H activation relative to the ene-type reaction was observed with aldehydes having unsaturation both at terminal and internal positions.

SELECTION OF CITATIONS
SEARCH DETAIL
...